Izoflawony a utrata masy kostnej u kobiet w okresie pomenopauzalnym. I. Wpływ produktów i preparatów z soi na metabolizm kostny

1. Mirza F.S., Prestwood K.M.: Bone health and aging: implications for menopause. Endocrinol. Metab. Clin. North Am. 2004, 33, 741. 2. Ahlborg H.G., Johnell O., Turner C.H. i wsp.: Bone loss and bone size after menopause. N. Engl. J. Med. 2003, 349, 327. 3. Lorenc R.S., Kruk M.: Osteoporoza okołomenopauzalna. W: Pertyński T. editor. Diagnostyka i terapia wieku menopauzalnego. Wrocław, Urban & Partner. 2004, 65. 4. Harris S., Dawson-Hughes B.: Rates of change in bone mineral density of the spine, heel, femoral neck and radius in healthy postmenopausal women. J. Bone Miner. Res. 1992, 17, 87. 5. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. WHO, Geneve 1994. 6. North American Menopause Society. The role of calcium in peri- and postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006, 13, 862. 7. Keen R.: Osteoporosis: strategies for prevention and management. Best Pract. Res. Clin. Rheumatol. 2007, 21, 109. 8. Cramer J.A., Lynch N.O., Gaudin A.F. i wsp.: The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin. Ther. 2006, 28, 1686. 9. Rossouw J.E., Anderson G.L., Prentice R.L. i wsp.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women´s Health Initiative randomized controlled trial. JAMA 2002, 288, 321. 10. Anderson G.L., Limacher M., Assaf A.R. i wsp.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women´s Health Initiative randomized controlled trial. JAMA 2004, 291, 1701. 11. Adams C., Cannell S.: Women´s beliefs about "natural" hormones and natural hormone replacement therapy. Menopause 2001, 8, 433. 12. Ling X., Lu A., Zhao X. i wsp.: Very low rates of hip fracture in Beijing, People´s Republic of China: the Beijing Osteoporosis Project. Am. J. Epidemiol. 1996, 144, 901. 13. Lauderdale D.S., Jacobsen S.J., Furner S.E. i wsp.: Hip fracture incidence among elderly Asian-American populations. Am. J. Epidemiol. 1997, 146, 502. 14. Greendale G.A., Fitz-Gerald G., Huang M.H. i wsp.: Dietary soy isoflavones and bone mineral density: results from the study of women´s health across the nation. Am. J. Epidemiol. 2002, 155, 746. 15. Nakamura T., Turner C.H., Yoshikawa T. i wsp.: Do variations in hip geometry explain differences in hip fracture risk between Japanese and white Americans? J. Bone Miner. Res. 1994, 9, 1071. 16. Chin K., Evans M.C., Cornish J. i wsp.: Differences in hip axis and femoral neck length in postmenopausal women of Polynesian, Asian and European origin. Osteoporos. Int. 1997, 7, 344. 17. Hirota T., Nara M., Ohguri M. i wsp.: Effect of diet and lifestyle on bone mass in Asian young women. Am. J. Clin. Nutr. 1992, 55, 1168. 18. Ho S.C., Chan S.G., Yi Q. i wsp.: Soy intake and the maintenance of peak bone mass in Hong-Kong Chinese women. J. Bone Miner. Res. 2001, 16, 1363. 19. Adlercreutz H., Mazur W.: Phyto-oestrogens and Western disease. Ann. Med. 1997, 29, 95. 20. Cooke G.M.: A review of the animal models used to investigate the health benefits of soy isoflavones. J. AOAC Int. 2006, 89, 1215. 21. Arjmandi B.H., Birnbaum R., Goyal N.V. i wsp.: Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavon content. Am. J. Clin. Nutr. 1998, Suppl. 68, 1364S. 22. Hotchkiss C.E., Weis C., Blaydes B. i wsp.: Multigenerational exposure to genistein does not increase bone mineral density in rats. Bone 2005, 37, 720. 23. Lees C.J., Ginn T.A.: Soy protein isolate diet does not prevent increased cortical bone turnover in ovariectomized macaques. Calcif. Tissue Int. 1968, 62, 557. 24. Setchell K.D.: Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am. J. Clin. Nutr. 1998, 68, 1333S. 25. Duncan A.M., Phipps W.R., Kurzer M.S.: Phyto-oestrogens. Best Practice & Res. Clin. Endocrinol. Metab. 2003, 17, 253. 26. Anderson J.J., Anthony M., Messina M. i wsp.: Effects of phyto-oestrogens on tissues. Nutr. Res. Rev. 1999, 12, 75. 27. Ilich J.Z., Brownbill R.A., Tamborini L.: Bone and nutrition in elderly women: Protein, energy, and calcium as main determinants of bone mineral density. Eur. J. Clin. Nutr. 2003, 57, 554. 28. Arjmandi B.H., Smith B.J.: Soy isoflavones´ osteoprotective role in postmenopausal women: mechanism of action. J. Nutr. Biochem. 2002, 13, 130. 29. Dang Z.C., Audinot V., Papapoulos S.E. i wsp.: Peroxisome proliferator-activated receptor γ (PPAR γ) as a molecular target for the soy phytoestrogen genistein. J. Biol. Chem. 2003, 278, 962. 30. Crisafulli A., Altavilla D., Squadrito G. i wsp.: Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor κB ligand-osteoprotegerin system in early postmenopausal women. J. Clin. Endocrinol. Metab. 2004, 89, 188. 31. Dang Z.C., Lowik C.: Dose-dependent effects of phytoestrogens on bone. Trends Endocrinol. Metab. 2005, 16, 207. 32. Potter S., Baum J., Teng H. i wsp.: Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am. J. Clin. Nutr. 1998, 68, 1375S. 33. Upmalis D.H., Lobo R., Bradley L. i wsp.: Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000, 7, 236. 34. Alekel D.L., Germain A.S., Peterson C.T. i wsp.: Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am. J. Clin. Nutr. 2000, 72, 844. 35. Wangen K.E., Duncan A.M., Merz-Demlow B.E. i wsp.: Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. J. Clin. Endocrinol. Metab. 2000, 85, 3043. 36. Knight D.C., Howes J.B., Eden J.A. i wsp.: Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation. Climacteric 2001, 4, 13. 37. Uesugi T., Fukui Y., Yamori Y.: Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: a four-week study. J. Am. Coll. Nutr. 2002, 21, 97. 38. Morabito N., Crisafulli A., Vergara C. i wsp.: Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J. Bone Miner. Res. 2002, 17, 1904. 39. Yamori Y., Moriguchi E.H., Teramoto T. i wsp.: Soybean isoflavones reduce postmenopausal bone resorption in female Japanese immigrants in Brazil: a ten-week study. J. Am. Coll. Nutr. 2002, 21, 560. 40. Arjmandi B.H., Khalil D.A., Smith B.J. i wsp.: Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. J. Clin. Endocrinol. Metab. 2003, 88, 1048. 41. Dalais F.S., Ebeling P.R., Kotsopoulos D. i wsp.: The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin. Endocrinol. 2003, 58, 704. 42. Murray M.J., Meyer W.R., Lessey B.A. i wsp.: Soy protein isolate with isoflavones does not prevent estradiol-induced endometrial hyperplasia in postmenopausal women: a pilot trial. Menopause 2003, 10, 456. 43. Chen Y.M., Ho S.C., Lam S.S. i wsp.: Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J. Clin. Endocrinol. Metab. 2003, 88, 4740. 44. Nikander E., Metsa-Keikkila M., Ylikorkola O. i wsp.: Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer. J. Clin. Endocrinol. Metab. 2004, 89, 1207, 45. Gallagher J.C., Satpathy R., Rafferty K. i wsp.: The effect of soy protein isolate on bone metabolism. Menopause 2004, 11, 290. 46. Kreijkamp-Kaspers S., Kok L., Grobbee D.E. i wsp.: Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 2004, 292, 65. 47. Lydeking-Olsen E., Beck-Jensen J.E., Setchell K.D. i wsp.: Soymilk or progesterone for prevention of bone loss-a 2 year randomized, placebo-controlled trial. Eur. J. Nutr. 2004, 43, 246. 48. Mori M., Aizawa T., Tokoro M. i wsp.: Soy isoflavone tablets reduce osteoporosis risk factors and obesity in middle-aged Japonase women. Clin. Exp. Pharmacol. Physiol. 2004, 31, Suppl 2, 39S. 49. Roughead Z.K., Hunt J.R., Johnson L.K. i wsp.: Controlled substitution of soy protein for meat protein: effects on calcium retention, bone, and cardiovascular health indices in postmenopausal women. J. Clin. Endocrinol. Metab. 2005, 90, 181. 50. Arjmandi B.H., Lucas E.A., Khalil D.A. i wsp.: One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr. J. 2005, 4, 8. 51. Albertazzi P., Steel S.A., Bottazzi M.: Effect of pure genistein on bone markers and hot flushes. Climacteric 2005, 8, 371. 52. Ye Y.B., Tang X.Y., Verbruggen M.A. i wsp.: Soy isoflavones attenuate bone loss in early postmenopausal Chinese women. A single-blind randomized, placebo-controlled trial. Eur. J. Nutr. 2006, 45, 327. 53. Newton K.M., LaCroix A.Z., Levy L. i wsp.: Soy protein and bone mineral density in older men and women: a randomized trial. Maturitas 2006, 55, 270. 54. Cheong J.M., Martin B.R., Jackson G.S. i wsp.: Soy isoflavones do not affect bone resorption in postmenopausal women: a dose-response study using a novel approach with ⁴¹Ca. J. Clin. Endocrinol. Metab. 2007, 92, 577. 55. Marini H., Minutoli L., Polito F. i wsp.: Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women. A randomized trial. Ann. Intern. Med. 2007, 146, 839. 56. Sugimoto T., Nishiyama K., Kuribayashi F. i wsp.: Serum levels of insulin-like growth factor (IGF)-1, IGF-binding protein (IGFBF)-2, and (IGFBF-)3 in osteoporotic patients with and without spinal fractures. J. Bone Miner. Res. 1997, 12, 1272. 57. Zhang X., Shu X.O., Li H. i wsp.: Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch. Intern. Med. 2005, 165, 1890.